High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis

E. Jane Kicklighter, Kang H. Lee, Kathleen C. Barracchini, Maria Bettinotti, Regina Norris, Toni B. Simonis, David Stroncek, Francesco M. Marincola

Research output: Contribution to journalArticle

Abstract

HLA-A02* has become an important target for cytotoxic T lymphocyte- based immunotherapy reflecting the high prevalence of this allele in patient populations. There are at least 26 different A*02 alleles, and their subtype specificity has significant functional implications for T-cell-mediated recognition of immunologic targets. We have developed a novel method for HLA- A*02 allelic screening using directed heteroduplex analysis (DHDA). DNA samples from Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (EBV-B) representing 10 different HLA-A*02 alleles (0201, 0202, 0204, 0205, 0206, 0208, 0210, 0211, 0216, 0217) were prepared. In addition, DNA was prepared from 81 individuals representing a wide variety of A*02 subtypes previously determined by sequence specific primer (SSP) polymerase chain reaction (PCR) including individuals heterozygous for two A*02 specificities. Probes and samples were generated by PCR amplification using HLA-A*02 specific primers encompassing exons 2 and 3, where most of the functionally significant allelic polymorphism is clustered. DHDA was performed by generating heteroduplex molecules composed of a fluorescein- labeled allelic probe sequence and an unlabeled allelic PCR product. Gel retardation was consistent for allele-probe combinations. We were able to identify several A*02 alleles prepared from EBV-B cell lines that, when used as probes, had very impressive specificity and sensitivity. Combinations of two probes were identified (0205 + 0211 and 0208 + 0211) that allowed differentiation of A*0201 alleles from all other A*02 alleles tested. All samples typed by probe combinations had DHDA typing and SSP typing confirmed by DNA sequencing. This study expands the molecular typing repertoire available to the modem HLA laboratory, and shows that DHDA has significant promise as a reliable screening method for HLA A*02 subtyping.

Original languageEnglish (US)
Pages (from-to)219-228
Number of pages10
JournalJournal of Immunotherapy
Volume22
Issue number3
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Heteroduplex Analysis
Alleles
HLA-A Antigens
Human Herpesvirus 4
Polymerase Chain Reaction
Modems
Molecular Typing
Cell Line
DNA
Cytotoxic T-Lymphocytes
HLA-A*02:01 antigen
Fluorescein
DNA Sequence Analysis
varespladib methyl
Immunotherapy
Exons
B-Lymphocytes
Gels
T-Lymphocytes
Sensitivity and Specificity

Keywords

  • Directed heteroduplex analysis
  • HLA-A*0201
  • Subtyping

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Kicklighter, E. J., Lee, K. H., Barracchini, K. C., Bettinotti, M., Norris, R., Simonis, T. B., ... Marincola, F. M. (1999). High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis. Journal of Immunotherapy, 22(3), 219-228. https://doi.org/10.1097/00002371-199905000-00004

High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis. / Kicklighter, E. Jane; Lee, Kang H.; Barracchini, Kathleen C.; Bettinotti, Maria; Norris, Regina; Simonis, Toni B.; Stroncek, David; Marincola, Francesco M.

In: Journal of Immunotherapy, Vol. 22, No. 3, 1999, p. 219-228.

Research output: Contribution to journalArticle

Kicklighter, EJ, Lee, KH, Barracchini, KC, Bettinotti, M, Norris, R, Simonis, TB, Stroncek, D & Marincola, FM 1999, 'High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis', Journal of Immunotherapy, vol. 22, no. 3, pp. 219-228. https://doi.org/10.1097/00002371-199905000-00004
Kicklighter, E. Jane ; Lee, Kang H. ; Barracchini, Kathleen C. ; Bettinotti, Maria ; Norris, Regina ; Simonis, Toni B. ; Stroncek, David ; Marincola, Francesco M. / High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis. In: Journal of Immunotherapy. 1999 ; Vol. 22, No. 3. pp. 219-228.
@article{4d768542697344d3898acfeaf0008416,
title = "High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis",
abstract = "HLA-A02* has become an important target for cytotoxic T lymphocyte- based immunotherapy reflecting the high prevalence of this allele in patient populations. There are at least 26 different A*02 alleles, and their subtype specificity has significant functional implications for T-cell-mediated recognition of immunologic targets. We have developed a novel method for HLA- A*02 allelic screening using directed heteroduplex analysis (DHDA). DNA samples from Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (EBV-B) representing 10 different HLA-A*02 alleles (0201, 0202, 0204, 0205, 0206, 0208, 0210, 0211, 0216, 0217) were prepared. In addition, DNA was prepared from 81 individuals representing a wide variety of A*02 subtypes previously determined by sequence specific primer (SSP) polymerase chain reaction (PCR) including individuals heterozygous for two A*02 specificities. Probes and samples were generated by PCR amplification using HLA-A*02 specific primers encompassing exons 2 and 3, where most of the functionally significant allelic polymorphism is clustered. DHDA was performed by generating heteroduplex molecules composed of a fluorescein- labeled allelic probe sequence and an unlabeled allelic PCR product. Gel retardation was consistent for allele-probe combinations. We were able to identify several A*02 alleles prepared from EBV-B cell lines that, when used as probes, had very impressive specificity and sensitivity. Combinations of two probes were identified (0205 + 0211 and 0208 + 0211) that allowed differentiation of A*0201 alleles from all other A*02 alleles tested. All samples typed by probe combinations had DHDA typing and SSP typing confirmed by DNA sequencing. This study expands the molecular typing repertoire available to the modem HLA laboratory, and shows that DHDA has significant promise as a reliable screening method for HLA A*02 subtyping.",
keywords = "Directed heteroduplex analysis, HLA-A*0201, Subtyping",
author = "Kicklighter, {E. Jane} and Lee, {Kang H.} and Barracchini, {Kathleen C.} and Maria Bettinotti and Regina Norris and Simonis, {Toni B.} and David Stroncek and Marincola, {Francesco M.}",
year = "1999",
doi = "10.1097/00002371-199905000-00004",
language = "English (US)",
volume = "22",
pages = "219--228",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis

AU - Kicklighter, E. Jane

AU - Lee, Kang H.

AU - Barracchini, Kathleen C.

AU - Bettinotti, Maria

AU - Norris, Regina

AU - Simonis, Toni B.

AU - Stroncek, David

AU - Marincola, Francesco M.

PY - 1999

Y1 - 1999

N2 - HLA-A02* has become an important target for cytotoxic T lymphocyte- based immunotherapy reflecting the high prevalence of this allele in patient populations. There are at least 26 different A*02 alleles, and their subtype specificity has significant functional implications for T-cell-mediated recognition of immunologic targets. We have developed a novel method for HLA- A*02 allelic screening using directed heteroduplex analysis (DHDA). DNA samples from Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (EBV-B) representing 10 different HLA-A*02 alleles (0201, 0202, 0204, 0205, 0206, 0208, 0210, 0211, 0216, 0217) were prepared. In addition, DNA was prepared from 81 individuals representing a wide variety of A*02 subtypes previously determined by sequence specific primer (SSP) polymerase chain reaction (PCR) including individuals heterozygous for two A*02 specificities. Probes and samples were generated by PCR amplification using HLA-A*02 specific primers encompassing exons 2 and 3, where most of the functionally significant allelic polymorphism is clustered. DHDA was performed by generating heteroduplex molecules composed of a fluorescein- labeled allelic probe sequence and an unlabeled allelic PCR product. Gel retardation was consistent for allele-probe combinations. We were able to identify several A*02 alleles prepared from EBV-B cell lines that, when used as probes, had very impressive specificity and sensitivity. Combinations of two probes were identified (0205 + 0211 and 0208 + 0211) that allowed differentiation of A*0201 alleles from all other A*02 alleles tested. All samples typed by probe combinations had DHDA typing and SSP typing confirmed by DNA sequencing. This study expands the molecular typing repertoire available to the modem HLA laboratory, and shows that DHDA has significant promise as a reliable screening method for HLA A*02 subtyping.

AB - HLA-A02* has become an important target for cytotoxic T lymphocyte- based immunotherapy reflecting the high prevalence of this allele in patient populations. There are at least 26 different A*02 alleles, and their subtype specificity has significant functional implications for T-cell-mediated recognition of immunologic targets. We have developed a novel method for HLA- A*02 allelic screening using directed heteroduplex analysis (DHDA). DNA samples from Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (EBV-B) representing 10 different HLA-A*02 alleles (0201, 0202, 0204, 0205, 0206, 0208, 0210, 0211, 0216, 0217) were prepared. In addition, DNA was prepared from 81 individuals representing a wide variety of A*02 subtypes previously determined by sequence specific primer (SSP) polymerase chain reaction (PCR) including individuals heterozygous for two A*02 specificities. Probes and samples were generated by PCR amplification using HLA-A*02 specific primers encompassing exons 2 and 3, where most of the functionally significant allelic polymorphism is clustered. DHDA was performed by generating heteroduplex molecules composed of a fluorescein- labeled allelic probe sequence and an unlabeled allelic PCR product. Gel retardation was consistent for allele-probe combinations. We were able to identify several A*02 alleles prepared from EBV-B cell lines that, when used as probes, had very impressive specificity and sensitivity. Combinations of two probes were identified (0205 + 0211 and 0208 + 0211) that allowed differentiation of A*0201 alleles from all other A*02 alleles tested. All samples typed by probe combinations had DHDA typing and SSP typing confirmed by DNA sequencing. This study expands the molecular typing repertoire available to the modem HLA laboratory, and shows that DHDA has significant promise as a reliable screening method for HLA A*02 subtyping.

KW - Directed heteroduplex analysis

KW - HLA-A0201

KW - Subtyping

UR - http://www.scopus.com/inward/record.url?scp=0032934228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032934228&partnerID=8YFLogxK

U2 - 10.1097/00002371-199905000-00004

DO - 10.1097/00002371-199905000-00004

M3 - Article

C2 - 10335481

AN - SCOPUS:0032934228

VL - 22

SP - 219

EP - 228

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 3

ER -